Cargando…
NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA
BACKGROUNDS: Evaluation of quality of life (QOL) has been considered as an indispensable modality for assessment of treatment impact for patients with malignant brain tumor, especially glioblastoma. However, changes in patients’ QOL under clinical practice with current standard of care (SOC) have no...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213115/ http://dx.doi.org/10.1093/noajnl/vdz039.135 |
_version_ | 1783531732561035264 |
---|---|
author | Yamagishi, Yuki Taku, Mikiko Hanayama, Naomi Saito, Kuniaki Kobayashi, Keiichi Yamada, Shin Okajima, Yasutomo Shiokawa, Yoshiaki Nagane, Motoo |
author_facet | Yamagishi, Yuki Taku, Mikiko Hanayama, Naomi Saito, Kuniaki Kobayashi, Keiichi Yamada, Shin Okajima, Yasutomo Shiokawa, Yoshiaki Nagane, Motoo |
author_sort | Yamagishi, Yuki |
collection | PubMed |
description | BACKGROUNDS: Evaluation of quality of life (QOL) has been considered as an indispensable modality for assessment of treatment impact for patients with malignant brain tumor, especially glioblastoma. However, changes in patients’ QOL under clinical practice with current standard of care (SOC) have not been clearly and routinely explored, so that solid baseline QOL data under SOC are not available for reliable comparison with those with novel treatments. Here we retrospectively examined changes in QOL during SOC in glioblastoma patients. PATIENTS AND METHODS: Patients with histologically confirmed glioblastoma treated in our institute from April 2016 to April 2019, who underwent QOL evaluations using EORTC QLQ-C-30/BN-20 were eligible. Outcomes were assessed with clinical factors including therapeutic regimens. RESULTS: Forty-two patients, median age 64 yo (25–87), male/female 26/16, were identified having longitudinal QOL data along with medical records. Median initial KPS and mini-mental state examination (MMSE) score were 70 (20–90) and 27, respectively, suggesting this cohort containing those in good performance status. In four patients whose QOL queries were answered by a family, median MMSE was 16, indicating the impaired NCF affect self-report ability. Long term survivors without progression remained at an adequate functional scale level, while those who recurred declined in functional scale after progression, often accompanied with an increase in symptom scales associated with tumor location. The domains of declined functional scales varied among patients, and there was no clear tendency associated with patients’ backgrounds such as age and gender. The functional scale level improved in most cases when the recurrent disease was successfully treated, but it gradually declined in a stepwise fashion by repeated recurrences. CONCLUSIONS: Changes in QOL in patients with glioblastoma were found to associate with disease status. The small number of patients who could be evaluated for QOL over time prevented extracting significant factors affecting QOL outcomes. |
format | Online Article Text |
id | pubmed-7213115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72131152020-07-07 NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA Yamagishi, Yuki Taku, Mikiko Hanayama, Naomi Saito, Kuniaki Kobayashi, Keiichi Yamada, Shin Okajima, Yasutomo Shiokawa, Yoshiaki Nagane, Motoo Neurooncol Adv Abstracts BACKGROUNDS: Evaluation of quality of life (QOL) has been considered as an indispensable modality for assessment of treatment impact for patients with malignant brain tumor, especially glioblastoma. However, changes in patients’ QOL under clinical practice with current standard of care (SOC) have not been clearly and routinely explored, so that solid baseline QOL data under SOC are not available for reliable comparison with those with novel treatments. Here we retrospectively examined changes in QOL during SOC in glioblastoma patients. PATIENTS AND METHODS: Patients with histologically confirmed glioblastoma treated in our institute from April 2016 to April 2019, who underwent QOL evaluations using EORTC QLQ-C-30/BN-20 were eligible. Outcomes were assessed with clinical factors including therapeutic regimens. RESULTS: Forty-two patients, median age 64 yo (25–87), male/female 26/16, were identified having longitudinal QOL data along with medical records. Median initial KPS and mini-mental state examination (MMSE) score were 70 (20–90) and 27, respectively, suggesting this cohort containing those in good performance status. In four patients whose QOL queries were answered by a family, median MMSE was 16, indicating the impaired NCF affect self-report ability. Long term survivors without progression remained at an adequate functional scale level, while those who recurred declined in functional scale after progression, often accompanied with an increase in symptom scales associated with tumor location. The domains of declined functional scales varied among patients, and there was no clear tendency associated with patients’ backgrounds such as age and gender. The functional scale level improved in most cases when the recurrent disease was successfully treated, but it gradually declined in a stepwise fashion by repeated recurrences. CONCLUSIONS: Changes in QOL in patients with glioblastoma were found to associate with disease status. The small number of patients who could be evaluated for QOL over time prevented extracting significant factors affecting QOL outcomes. Oxford University Press 2019-12-16 /pmc/articles/PMC7213115/ http://dx.doi.org/10.1093/noajnl/vdz039.135 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Yamagishi, Yuki Taku, Mikiko Hanayama, Naomi Saito, Kuniaki Kobayashi, Keiichi Yamada, Shin Okajima, Yasutomo Shiokawa, Yoshiaki Nagane, Motoo NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA |
title | NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA |
title_full | NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA |
title_fullStr | NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA |
title_full_unstemmed | NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA |
title_short | NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA |
title_sort | nqpc-03 prognostic significance of quality-of-life evaluation over time in clinical practice for patients with glioblastoma |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213115/ http://dx.doi.org/10.1093/noajnl/vdz039.135 |
work_keys_str_mv | AT yamagishiyuki nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma AT takumikiko nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma AT hanayamanaomi nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma AT saitokuniaki nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma AT kobayashikeiichi nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma AT yamadashin nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma AT okajimayasutomo nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma AT shiokawayoshiaki nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma AT naganemotoo nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma |